PSP 001
Alternative Names: PEGIFNλ-chimera; PEGINF-L chimera; PEGinterferon λ1-λ3 chimera; PSP-001Latest Information Update: 28 Jun 2024
At a glance
- Originator Prosit Sole Biotechnology
- Class Antivirals; Interferons; Recombinant fusion proteins
- Mechanism of Action Interferon gamma replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Hepatitis B
- No development reported Norovirus infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Norovirus-infections(In volunteers) in USA (IV, Injection)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Norovirus-infections in China (IV, Injection)
- 17 May 2022 Prosit Sole Biotechnology intends to submit BLA in Norovirus infections in 2022 (Prosit Sole Biotechnology pipeline, May 2022)